Nurse Practitioner Medical
Resume:
MARY ROBINSON, R.N., M.S.N., N.P.
CURRICULUM VITAE
**** ********* ******, ********** *****, CA 92649
ACADEMIC AND PROFESSIONAL PREPARATION
**** ********** ***** **********, ***g Beach
Long Beach, CA
Master of Science, Nursing
1989 California State University, Long Beach
Long Beach, CA
Nurse Practitioner Certification
1988 Consortium of the California State University
Long Beach, CA
Bachelor of Science, Nursing
1986 El Camino College
Torrance, CA
Associate of Arts, Nursing
LICENSURE AND CERTIFICATION
Nursing License-State of California #388739
Nurse Practitioner License #4928
Furnishing License #4928
American Heart Association Basic CPR and ACLS Certified current
PROFESSIONAL EXPERIENCE
1/2010-current Research Across America
Santa Ana, CA
Clinical sub-investigator/coordinator responsible for
recruiting, screening and managing subjects in clinical studies,
performing histories, physicals, phlebotomy, IV insertion,
cardiac stress testing and lab/ecg interpretation.
Therapeutic areas of research: acne, dyslipidemias,
hypertension, coronary artery disease, claudication, diabetes
mellitus, diabetic neuropathy, vaccines, hormone replacement
therapy, fibromyalgia, osteoarthritis, rosacea.
2009-1/2010 Orange County Heart Institute and Research Center
Orange, CA
Clinical study manager/sub-investigator/coordinator responsible
for recruitment, screening subjects for clinical studies,
performing histories and physicals, phlebotomy, cardiac stress
testing and lab interpretation. Developed site's grant proposal
process, budget management and investigator written protocols.
Developed site's investigator driven research program.
Responsible for new business development and management of all
department research related activities. Developed site Standard
Operating Procedure guidelines. Therapeutic Areas of
Research/medical practice: hypertension, hyperlipidemia, atrial
fibrillation, congestive heart failure, pacemakers, AICD,
coronary artery disease, electron beam computed tomography, 64
slice angiography/PET perfusion, anti-coagulation.
2001-2009 OC Vital Imaging/Orange County Heart Institute
Orange, CA
Manager of outpatient imaging facility. Responsible for coronary
artery and full body interpretation of Electron Beam Computed
Tomography results for patients in an outpatient clinical
setting. Duties include patient education/treatment regarding
clinical findings, laboratory diagnostic services, triage
services, Coumadin clinic, Women's Heart Center coordinator and
diagnostic/treatment follow-up. Responsible for coordination of
radiology and cardiology services, new business development and
medical insurance coding/billing. Responsible for medical care
and organization of all procedures and follow-up for outpatient
angiography.
2000. University Clinical Investigators Inc.
Vice President of Nursing Services, Diabetes Research Center
Tustin, CA
Supervised staff of 12 clinical research associates in a
clinical research unit. Responsible for screening subjects for
clinical studies, performing histories and physicals, phlebotomy
and lab interpretation. Responsible for grant proposals and
budget management. Medically managed patients in an outpatient
diabetes/internal medicine clinic. Managed human resources:
payroll, medical insurance, 401 plan.
1998. University Clinical Investigators Inc.
CEO Diabetes Research Center
Tustin, CA
Responsible for administrative and financial aspects of a
clinical research unit, with gross business profits over 1.4
million first year of business. Conducted and managed
neuropathic, lipid, nephrology, hypertension, glycemic clinical
trials. Consistent top three national recruiter for many
clinical trials. National trainer for neuropathic trial
recruitment and outpatient surgical sural nerve biopsy
procurement. Managed grant proposals and responsible for
regulatory aspects of clinical trials conducted. Supervised
staff of 15, including consulting physicians, nurses and
research associates. Medically managed patient care in an
outpatient diabetes/internal medicine clinic.
1995. University of California, Irvine
Long Beach Veteran's Hospital and UCI Diabetes Center
Nurse Practitioner
Performed duties related to clinical research nurse for a Phase
II-IV trials:
Recruitment, patient matriculation, histories, physicals,
phlebotomy and IV infusions. Medically managed patient care in
an outpatient diabetes/internal medicine clinic.
1987. Torrance Memorial Hospital
Torrance, CA
Intensive Cardiac Care Nurse
Night relief supervisor for combined intensive and cardiac care
unit. Responsible for immediate postoperative care of open-heart
patients.
1985. Harbor-UCLA Medical Center
Torrance, CA
Medical Surgical Nurse
Floor nurse for general medical and surgical patients.
Responsible for all aspects of patient care including
intravenous infusions, medication dispensation, wound care and
chest management.
PROFESSIONAL MEMBERSHIPS
1992. American Association of Diabetes Educators, Certified Diabetes
Educator
1993. Chair, Professional Education Committee, American Diabetes
Association
2006-current California Board of Registered Nursing Expert Witness
Committee
2011-current American Association of Nurse Practitioners
HONORS
1989-1992 Sigma Theta Tau, Iota Eta Chapter, International Honor Society
of Nursing
PUBLICATIONS AND ABSTRACTS
Santora LJ, Marin, J., Vangrow, J., Minegar, C., Robinson, M., Mora, J.,
Friede, G., "Coronary Calcification in Body Builders Using Anabolic
Steroids." Preventative Cardiology, Fall 2006.
Green, DA, Arezzo., J.C., Brown. M.B., Charles, M.A., Robinson, M., "Effect
of Aldose Reductase Inhibition on Nerve Conduction and Morphometry in
Diabetic Neuropathy."
Charles, M.A., Selam, J.L., Chan, E., Woertz, L., Robinson, M. "The Use of
Glipizide for Remission Induction in New Onset Type I Diabetes."
Diabetologia 33: 690A, 1990.
Charles, M.A., Selam., J.L., Chan, E., Woertz, L., Robinson, M., Lozano, J.
"The Effects of Intensive Insulin Treatment and Glipizide Upon Remission
Induction and Endogenous Insulin Secretion in New Onset Type I Diebetes."
Diabetes (supplement) 40:57A, 1991.
Lee,Y., Robinson, M., Wong, N., Chan, E., Charles, M.A., "The Effect of
Pentoxyphylline on Diabetic Neuropathy." Journal of Diabetes and its
Complications 11:274-278, 1997.
Selam, J.L., Woertz, L., Robinson, M., Chan, E., Charles, M.A., "The Use of
Glipizide Combined with Intensive Insulin Treatment for the Induction of
Emissions in New Onset Adult Type I Diabetes." Autoimmunity 16-281-288,
1993.
CLINICAL TRIALS
2010 Glaxo- Observer-blind superior efficacy trial with
GlaxoSmithKline
SmithKline Biologicals' influenza vaccine in elderly subjects.
2010 Pfizer Inc. A Phase 3, Multi-Center, Randomized, Double-Blind,
Controlled
Study of the Long-Term Analgesic Efficacy and Safety of
***Alone or in Combination with Non-Steroidal Anti-
Inflammatory Drugs (NSAIDS) versus NSAIDS Alone in
Patients
with Osteoarthritis of the Knee or Hip.
2010 Glaxo- A Clinical Outcomes Study of *** versus Placebo in
SmithKline Subjects with Chronic Coronary Heart Disease to
Compare the
Incidence of Major Adverse Cardiovascular Events (MACE).
2010 Bayer Multi-center, open-label, uncontrolled study to
investigate the efficacy and safety of the ***containing
0.55 mg. ***and
2.1 mg. ***in a 21-day regimen for 13 cycles in 1650
healthy
female subjects.
2010 Abbott Phase III: Evaluation of *** on
Carotid Intima-Media Thickness (cIMT) in Subjects with
Type IIb Dyslipidemia with Residual Risk in Addition
to*** Therapy (FIRST) trial.
2010 Merck A worldwide, multicenter, double-blind, randomized,
parallel, placebo-controlled study to evaluate the long-
term efficacy, safety and tolerability of ***
and *** in patients with Dyslipidemia.
2010 Dynavax An observer-blinded, randomized, parallel-group, multi-
center study comparing the safety and immunogenicity
of *** to licensed Vaccine among healthy
subjects 40-70 years of age.
2010 Glaxo- A Clinical Outcomes Study of *** versus Placebo in
SmithKline Subjects Following Acute Coronary Syndrome to
Compare the
Incidence of Major Adverse Cardiovascular Events (MACE).
2010 Noven A Phase 3, Twenty Four Week, Multicenter, Double-
Blind,
Therapeutics Randomized, Placebo-Controlled, Efficacy and Safety Study
of *** Capsules in the Treatment of Vasomotor
Symptoms associated with Menopause.
2010 Forest A Multicenter, Randomized, Double-Blind, Placebo-
Controlled
Discontinuation Study to Evaluate the Durability of Effect
of *** for the Treatment of Fibromyalgia in Patients
with Long Term ***Treatment.
2010 Hoffman-La A randomized, double-blind, placebo-controlled clinical
trial to
Roche assess the effects of *** on cardiovascular
outcomes in subjects with inadequately controlled type 2
diabetes and established cardiovascular disease.
2010 Jazz Safety and Tolerability Study Comparing *** Given
as an Oral Solution to a Single-blinded Combination of Oral
tablets plus Oral Solution in Subjects with Fibromyalgia.
2010 Dynport A Phase 2b Randomized, Single-Blinded Study to Evaluate
the Safety and Immunogenicity of 80 ug Recombinant
Plague Vaccine (rF1v) With and Without Adjuvant at Two
Vaccination Schedules in Healthy Adult Volunteers.
2010 Cytokinetics A Phase II, Double-Blind, Randomized, Placebo-
Controlled, Three Way Crossover, Pharmacokinetic and
Pharmacodynamic Study of CK 2017357 In Patients with
Claudication.
2010 Novo Nordisk A 26 week, randomized, controlled, open label,
multicentre, multinational, treat to target trial
investigating the impact of dietary intervention on weight
change and the relationship between weight change and
baseline body max index (BMI) in subjects with type 2
diabetes inadequately controlled on oral antidiabetic drugs (OADs)
initiating insulin therapy with *** in combination with
2010 Trygg A randomized, double-blind, placebo-controlled, parallel
group
Pharma, LLC phase III study to assess efficacy and safety of ***
in subjects with severe hypertrygliceridemia.
2010 Pfizer A Phase 3 Double-Blind, Randomized, Placebo-
Controlled, Safety and Efficacy Study of once daily
controlled Release *** in the Treatment of
Patients with Fibromyalgia.
2010 Pfizer A Phase 3B multicenter, double-blind, randomized
withdrawal
and safety study of *** in the treatment of patients with
inadequately treated painful diabetic peripheral
neuropathy
2010 CPC A Phase II, Double-Blind, Randomized, placebo-
Controlled,
Three- Way Crossover, Pharmacokinetic and Pharmacodynamic
Study of ***In Patients With Claudication
2011 Vermillion A Clinical Trial for Evaluation of Vermillion's Blood Test
to
Predict the Probability of Peripheral Artery Disease
2011 Merck A Phase III Multicenter, Double-Blind, Crossover Design
Study to
Evaluate Lipid-Altering Efficacy and Safety of 1g/10 mg
Extended
Release Combination Tablets in Patients with
Primary Hypercholesterolemia or Mixed Dyslipidemia
2011 Pfizer Molecular Characterization of Familial
Hypercholesterolemia
2011 Astute A Normal Donor Sample Collection Study in Healthy
Adults
2011 Caris The Caris Biorepository Research Protocol
2011 Watson A Multi-Center, Double-Blind, Randomized, Vehicle-
Controlled,
Parallel-Group Study Comparing *** and *** ***Topical Gel
0.1%/2.5% (Watson Laboratories, Inc.) to *** (Galderma
Laboratories, L.P., *** and *** *** Topical Gel 0.1%/2.5%)
and both active treatments to a vehicle control in the
treatment of
Acne Vulgaris
2011 Pfizer A Phase 3B multicenter, double-blind, randomized,
placebo-
controlled, 2-way crossover study of *** in the treatment
of
fibromyalgia with concurrent antidepressant therapy for
comorbid
depression.
2012 Galderma A Phase III Randomized, Double-Blind, 12-week vehicle-
controlled, parallel-group study assessing the efficacy and
safety of *** cream versus vehicle cream in
subjects with papulopustular rosacea, followed by a 40-week
investigator-blinded extension comparing the long-term
safety of ***1% cream versus ***15% gel.
2012 Xoma A Multicenter, Randomized, Double-Blind, Parallel-Group
Study
Evaluating the Efficacy and Safety of a Fixed-Dose
Combination
Of *** and *** in Subjects with Essential Hypertension
2012 Bayer A Randomized, Double-Blind, Vehicle-controlled,
multicenter,
parallel-group clinical trial to assess the safety and
efficacy of Azelaic Acid Foam 15% topically applied twice
daily for 12 weeks in patients with papulopustular rosacea
2012 Taro A Multi-center, Double-Blind, Randomized, Placebo-controlled
Parallel-Group Study, Comparing Adapalene and Benzoyl Peroxide Gel
0.1%/2.5% to Epiduo, and both active treatments to a
placebo control in the treatment of acne vulgaris.
2013 Amgen A Double-blind, Randomized, Placebo and Ezetimibe Controlled,
Multicenter Study to Evaluate Safety, Tolerability and
Efficacy of AMG 145 on LDL-c in Combination with Statin
Therapy in Subjects with Primary Hypercholesterolemia and
Mixed Dyslipidemia
2013 Amylin A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-
controlled, Multicenter Study to compare the glycemic
effects, safety and tolerability of Exenatide once weekly
suspension to Exenatide twice daily in subjects with Type 2
diabetes mellitus
2013 Tolmar A Double-Blind, Randomized, Parallel-group, Vehicle-
controlled, Multicenter study comparing Clindamycin
Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% Generic to
reference Listed Drug in the treatment of acne vulgaris
2013 Lithera A Multi-center, Randomized, Double-Blind, Placebo-
Controlled, Dose-Ranging Study evaluating the safety and
efficacy of Salmeterol Xinafoate (SX) in the aesthetic
treatment of disproportionate abdominal bulging due to
excess subcutaneous fat in healthy, non-obese patients
Contact this candidate